179 related articles for article (PubMed ID: 31988145)
1. Knowledge of Potential Harms and Benefits of Tamoxifen among Women Considering Breast Cancer Preventive Therapy.
Thorneloe RJ; Hall LH; Walter FM; Side L; Lloyd KE; Smith SG;
Cancer Prev Res (Phila); 2020 Apr; 13(4):411-422. PubMed ID: 31988145
[TBL] [Abstract][Full Text] [Related]
2. Beliefs About Medication and Uptake of Preventive Therapy in Women at Increased Risk of Breast Cancer: Results From a Multicenter Prospective Study.
Thorneloe RJ; Horne R; Side L; Wolf MS; Smith SG;
Clin Breast Cancer; 2019 Feb; 19(1):e116-e126. PubMed ID: 30518498
[TBL] [Abstract][Full Text] [Related]
3. Women's decisions regarding tamoxifen for breast cancer prevention: responses to a tailored decision aid.
Fagerlin A; Zikmund-Fisher BJ; Nair V; Derry HA; McClure JB; Greene S; Stark A; Hensley Alford S; Lantz P; Hayes DF; Wiese C; Claud Zweig S; Pitsch R; Jankovic A; Ubel PA
Breast Cancer Res Treat; 2010 Feb; 119(3):613-20. PubMed ID: 19908143
[TBL] [Abstract][Full Text] [Related]
4. Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction.
Melnikow J; Paterniti D; Azari R; Kuenneth C; Birch S; Kuppermann M; Nuovo J; Keyzer J; Henderson S
Cancer; 2005 May; 103(10):1996-2005. PubMed ID: 15825209
[TBL] [Abstract][Full Text] [Related]
5. Patient reluctance toward tamoxifen use for breast cancer primary prevention.
Port ER; Montgomery LL; Heerdt AS; Borgen PI
Ann Surg Oncol; 2001 Aug; 8(7):580-5. PubMed ID: 11508619
[TBL] [Abstract][Full Text] [Related]
6. Assessment of Breast Cancer Patients' Knowledge and Decisional Conflict Regarding Tamoxifen Use.
Kim SI; Lee Y; Son Y; Jun SY; Yun S; Bae HS; Lim MC; Jung SY; Joo J; Lee ES
J Korean Med Sci; 2015 Nov; 30(11):1604-10. PubMed ID: 26539004
[TBL] [Abstract][Full Text] [Related]
7. The benefits and costs of tamoxifen for breast cancer prevention.
Eckermann SD; Martin AJ; Stockler MR; Simes RJ
Aust N Z J Public Health; 2003; 27(1):34-40. PubMed ID: 14705265
[TBL] [Abstract][Full Text] [Related]
8. News media coverage of screening mammography for women in their 40s and tamoxifen for primary prevention of breast cancer.
Schwartz LM; Woloshin S
JAMA; 2002 Jun; 287(23):3136-42. PubMed ID: 12069679
[TBL] [Abstract][Full Text] [Related]
9. My Lived Experiences Are More Important Than Your Probabilities: The Role of Individualized Risk Estimates for Decision Making about Participation in the Study of Tamoxifen and Raloxifene (STAR).
Holmberg C; Waters EA; Whitehouse K; Daly M; McCaskill-Stevens W
Med Decis Making; 2015 Nov; 35(8):1010-22. PubMed ID: 26183166
[TBL] [Abstract][Full Text] [Related]
10. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition.
Chlebowski RT; Col N; Winer EP; Collyar DE; Cummings SR; Vogel VG; Burstein HJ; Eisen A; Lipkus I; Pfister DG;
J Clin Oncol; 2002 Aug; 20(15):3328-43. PubMed ID: 12149307
[TBL] [Abstract][Full Text] [Related]
11. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
Fisher B; Costantino JP; Wickerham DL; Cecchini RS; Cronin WM; Robidoux A; Bevers TB; Kavanah MT; Atkins JN; Margolese RG; Runowicz CD; James JM; Ford LG; Wolmark N
J Natl Cancer Inst; 2005 Nov; 97(22):1652-62. PubMed ID: 16288118
[TBL] [Abstract][Full Text] [Related]
12. Should menopausal women at increased risk for breast cancer use tamoxifen, raloxifene, or hormone therapy?: a framework for personalized risk assessment and counseling.
Matloff ET; Shannon KM; Moyer A; Col NF
J Cancer Educ; 2007; 22(1):10-4. PubMed ID: 17570802
[TBL] [Abstract][Full Text] [Related]
13. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial.
Cuzick J; Forbes J; Edwards R; Baum M; Cawthorn S; Coates A; Hamed A; Howell A; Powles T;
Lancet; 2002 Sep; 360(9336):817-24. PubMed ID: 12243915
[TBL] [Abstract][Full Text] [Related]
14. Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force.
Nelson HD; Smith ME; Griffin JC; Fu R
Ann Intern Med; 2013 Apr; 158(8):604-14. PubMed ID: 23588749
[TBL] [Abstract][Full Text] [Related]
15. Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors.
Bober SL; Hoke LA; Duda RB; Regan MM; Tung NM
J Clin Oncol; 2004 Dec; 22(24):4951-7. PubMed ID: 15598980
[TBL] [Abstract][Full Text] [Related]
16. Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention.
Freedman AN; Graubard BI; Rao SR; McCaskill-Stevens W; Ballard-Barbash R; Gail MH
J Natl Cancer Inst; 2003 Apr; 95(7):526-32. PubMed ID: 12671020
[TBL] [Abstract][Full Text] [Related]
17. Providing accurate information to women about tamoxifen therapy for breast cancer: current indications, effects, and controversies.
Pasacreta JV; McCorkle R
Oncol Nurs Forum; 1998 Oct; 25(9):1577-83. PubMed ID: 9802053
[TBL] [Abstract][Full Text] [Related]
18. The effect of information about the benefits and harms of mammography on women's decision-making: study protocol for a randomized controlled trial.
Carles M; Martínez-Alonso M; Pons A; Pérez-Lacasta MJ; Perestelo-Pérez L; Sala M; Vidal C; Garcia M; Toledo-Chávarri A; Codern N; Feijoo-Cid M; Romero A; Pla R; Soler-González J; Castells X; Rué M;
Trials; 2017 Sep; 18(1):426. PubMed ID: 28899412
[TBL] [Abstract][Full Text] [Related]
19. Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer.
Bui KT; Willson ML; Goel S; Beith J; Goodwin A
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD013538. PubMed ID: 32141074
[TBL] [Abstract][Full Text] [Related]
20. Women's decision making about whether or not to use breast cancer chemoprevention.
Altschuler A; Somkin CP
Women Health; 2005; 41(2):81-95. PubMed ID: 16219589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
